Cargando…
Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
Short chain fructo-oligosaccharides (scFOS) are well-recognized prebiotic fibers. Fossence™ (FOSS) is a scFOS that has been produced from sucrose via a proprietary fermentation process and has not been tested for its digestibility or glucose/insulin response (GR and IR, respectively). The present ra...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102419/ https://www.ncbi.nlm.nih.gov/pubmed/33997376 http://dx.doi.org/10.1016/j.heliyon.2021.e06805 |
_version_ | 1783689099029250048 |
---|---|
author | Shah, Priyali Wolever, Thomas MS. Jenkins, Alexandra L. Ezatagha, Adish Campbell, Janice Zurbau, Andreea Jain, Manish Gote, Manoj Bhaduri, Anirban Mullick, Ashim |
author_facet | Shah, Priyali Wolever, Thomas MS. Jenkins, Alexandra L. Ezatagha, Adish Campbell, Janice Zurbau, Andreea Jain, Manish Gote, Manoj Bhaduri, Anirban Mullick, Ashim |
author_sort | Shah, Priyali |
collection | PubMed |
description | Short chain fructo-oligosaccharides (scFOS) are well-recognized prebiotic fibers. Fossence™ (FOSS) is a scFOS that has been produced from sucrose via a proprietary fermentation process and has not been tested for its digestibility or glucose/insulin response (GR and IR, respectively). The present randomized, controlled, cross-over study was conducted in 3 phases to explore GR and IR to ingestion of FOSS, when replaced by/added to available-carbohydrates (avCHO) among 25 healthy adults (40 ± 14years). In each phase GR and IR elicited by 3–4 test-meals were measured among the fasted recruited subjects. The interventional test meals were as follows: Phase-1, water alone or 10g FOSS or 10g Dextrose in 250ml water; Phase-2, 250ml water containing Dextrose:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15; Phase-3 portions of white-bread (WB) containing avCHO:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15. Blood samples (finger prick method) were collected at fasting and 15, 30, 45, 60, 90 and 120 min after start of test meal ingestion. Plasma glucose and serum insulin were analyzed utilizing standard methods. The primary endpoint was differences in glucose IAUC. All subjects provided their written consent to participate in the study (ClinicalTrials.gov: NCT03755232). The results demonstrated that FOSS, when consumed alone, showed no raise in glycaemia or insulinemia and was statistically equivalent to response of water alone. GR and IR elicited by dextrose:FOSS and WB:FOSS test-meals of Phase 2 and Phase 3, were statistically equivalent to the respective test-meals without FOSS. Result of the 3 phases support the hypothesis that FOSS is resistant to breakdown and is indigestible in the human small-intestine, and therefore can be classified as an unavailable carbohydrate that does not raise post prandial blood glucose or insulin. FOSS, being sweet to taste, may be an acceptable sugar replacer in beverages without compromising their taste and sensory qualities. |
format | Online Article Text |
id | pubmed-8102419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81024192021-05-14 Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial Shah, Priyali Wolever, Thomas MS. Jenkins, Alexandra L. Ezatagha, Adish Campbell, Janice Zurbau, Andreea Jain, Manish Gote, Manoj Bhaduri, Anirban Mullick, Ashim Heliyon Research Article Short chain fructo-oligosaccharides (scFOS) are well-recognized prebiotic fibers. Fossence™ (FOSS) is a scFOS that has been produced from sucrose via a proprietary fermentation process and has not been tested for its digestibility or glucose/insulin response (GR and IR, respectively). The present randomized, controlled, cross-over study was conducted in 3 phases to explore GR and IR to ingestion of FOSS, when replaced by/added to available-carbohydrates (avCHO) among 25 healthy adults (40 ± 14years). In each phase GR and IR elicited by 3–4 test-meals were measured among the fasted recruited subjects. The interventional test meals were as follows: Phase-1, water alone or 10g FOSS or 10g Dextrose in 250ml water; Phase-2, 250ml water containing Dextrose:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15; Phase-3 portions of white-bread (WB) containing avCHO:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15. Blood samples (finger prick method) were collected at fasting and 15, 30, 45, 60, 90 and 120 min after start of test meal ingestion. Plasma glucose and serum insulin were analyzed utilizing standard methods. The primary endpoint was differences in glucose IAUC. All subjects provided their written consent to participate in the study (ClinicalTrials.gov: NCT03755232). The results demonstrated that FOSS, when consumed alone, showed no raise in glycaemia or insulinemia and was statistically equivalent to response of water alone. GR and IR elicited by dextrose:FOSS and WB:FOSS test-meals of Phase 2 and Phase 3, were statistically equivalent to the respective test-meals without FOSS. Result of the 3 phases support the hypothesis that FOSS is resistant to breakdown and is indigestible in the human small-intestine, and therefore can be classified as an unavailable carbohydrate that does not raise post prandial blood glucose or insulin. FOSS, being sweet to taste, may be an acceptable sugar replacer in beverages without compromising their taste and sensory qualities. Elsevier 2021-04-28 /pmc/articles/PMC8102419/ /pubmed/33997376 http://dx.doi.org/10.1016/j.heliyon.2021.e06805 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Shah, Priyali Wolever, Thomas MS. Jenkins, Alexandra L. Ezatagha, Adish Campbell, Janice Zurbau, Andreea Jain, Manish Gote, Manoj Bhaduri, Anirban Mullick, Ashim Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial |
title | Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial |
title_full | Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial |
title_fullStr | Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial |
title_full_unstemmed | Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial |
title_short | Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial |
title_sort | acute glycemic and insulin response of fossence™ alone, or when substituted or added to a carbohydrate challenge: a three-phase, acute, randomized, cross-over, double blind clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102419/ https://www.ncbi.nlm.nih.gov/pubmed/33997376 http://dx.doi.org/10.1016/j.heliyon.2021.e06805 |
work_keys_str_mv | AT shahpriyali acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT woleverthomasms acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT jenkinsalexandral acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT ezataghaadish acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT campbelljanice acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT zurbauandreea acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT jainmanish acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT gotemanoj acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT bhadurianirban acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial AT mullickashim acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial |